Chief.AI, in partnership with Medicines Discovery Catapult (MDC), has launched the first no-code, pay as you go, AI platform for drug discovery.
Medicines Discovery Catapult (MDC) is proud to announce an extension to its talented workforce.
The Alderley Park facility received the award for its integral role in establishing the Lighthouse Laboratory network.
The UK’s centre for therapeutics innovation, Medicines Discovery Catapult (MDC), has received a £5 million grant to build a Translational Research Facility in Infectious Disease on its Alderley Park site.
Chris Molloy, Chief Executive Officer of the Medicines Discovery Catapult will be stepping down in September 2021 after five years in the role.
Psychiatric drug discovery must be a truly collaborative process if it is to be successful.
While student perceptions of careers in science may come with a lack of diversity, the Covid-19 pandemic has highlighted the important contributions made by scientists and healthcare professionals…
Medicines Discovery Catapult’s newly appointed Chief Business Officer, Dr Nicola Heron MBA sets out her intention to support up-and-coming innovators…
Ahead Of International Day Of Women And Girls In Science, Three Covid Scientists Share Their Experience of Battling the Pandemic.
See how we can help support you with your next drug discovery project.
Speak to us
